CGTX Stock Overview
A clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Cognition Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.42 |
52 Week High | US$2.95 |
52 Week Low | US$0.34 |
Beta | 1.25 |
11 Month Change | -15.19% |
3 Month Change | -25.61% |
1 Year Change | -74.46% |
33 Year Change | -94.73% |
5 Year Change | n/a |
Change since IPO | -96.68% |
Recent News & Updates
Recent updates
Can Cognition Therapeutics (NASDAQ:CGTX) Afford To Invest In Growth?
Sep 06Cognition Therapeutics: Shines Less Bright After Phase 2 Results In Alzheimer's Disease
Jul 31Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?
May 22Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's
Apr 18Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation
Nov 30Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?
Aug 15Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans
Mar 17Cognition stock rises 12% on $2.14M grant from NIH for Alzheimer's study
Sep 27We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth
Aug 12Cognition's Alzheimer's candidate demonstrates mechanism of action; shares soar
Aug 05We're Not Very Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Mar 19Shareholder Returns
CGTX | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 5.4% | 0.9% | 1.1% |
1Y | -74.5% | 14.0% | 32.4% |
Return vs Industry: CGTX underperformed the US Pharmaceuticals industry which returned 14% over the past year.
Return vs Market: CGTX underperformed the US Market which returned 32.4% over the past year.
Price Volatility
CGTX volatility | |
---|---|
CGTX Average Weekly Movement | 14.2% |
Pharmaceuticals Industry Average Movement | 9.9% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 16.3% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CGTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CGTX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 27 | Lisa Ricciardi | www.cogrx.com |
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer’s disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.
Cognition Therapeutics, Inc. Fundamentals Summary
CGTX fundamental statistics | |
---|---|
Market cap | US$15.71m |
Earnings (TTM) | -US$34.27m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs CGTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CGTX income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$34.27m |
Earnings | -US$34.27m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.82 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did CGTX perform over the long term?
See historical performance and comparison